Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced it will release its financial results for the first quarter ended March 31, 2023, on May 8, 2023, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Vicarious Surgical is focused on advanced surgical robotics with the aim of enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Backed by prominent investors, including Bill Gates and Khosla Ventures, the company is known for its innovative approach that transports surgeons inside patients for minimally invasive surgeries. Stakeholders can access further information via the company's investor website.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in two upcoming investor conferences. The company aims to enhance surgical procedures through innovative robotics technology.
The first event is the Cowen 43rd Annual Healthcare Conference, featuring a fireside chat on March 8th at 9:50 a.m. ET. The second is the Oppenheimer 33rd Annual Healthcare Conference, with a virtual presentation scheduled for March 14th at 1:20 p.m. ET. Live and archived versions of these presentations will be available on the company's website.
Vicarious Surgical reported a cash burn of $67 million for 2022, meeting its objective, and announced initiatives to extend its cash runway. The company expects 2023 cash burn between $55-$65 million. Vicarious Surgical's operating expenses surged to $80.1 million in 2022 versus $38.2 million in 2021, with an adjusted net loss of $78.8 million, or $0.65 per share. Despite a GAAP net income of $5.2 million for the year, the company reported significant losses. Notable achievements include the completion of the Beta 2 robotic system and partnerships with major healthcare providers, enhancing its market position.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on February 13, 2023. A conference call will follow at 4:30 p.m. ET for management to discuss the results. Investors can join by calling +1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. The company develops advanced surgical robotics aimed at improving the efficiency of procedures and reducing costs, using proprietary technology to perform minimally invasive surgeries.
Vicarious Surgical Inc. (NYSE:RBOT) has appointed Dr. Victoria Carr-Brendel to its Board of Directors as of January 23, 2023. Dr. Carr-Brendel brings over 24 years of experience in medical device development and leadership roles, including her current position at Sonova Group. Her expertise is expected to enhance the company's efforts in bringing innovative surgical solutions to market. The announcement also includes the resignation of Phil Liang, a technology-focused venture capitalist. The company aims to improve surgical procedures' efficiency, outcomes, and costs through its unique robotic systems.
Vicarious Surgical Inc. (NYSE:RBOT) demonstrated its Beta 2 surgical robotic platform on December 6, 2022, highlighting advancements in technology and successful cadaveric testing. CEO Adam Sachs emphasized the importance of this milestone, while surgeon Dr. Igor Belyansky showcased the system’s innovative capabilities in a recent procedure. Collaborating with University Hospitals, the company aims to improve minimally invasive surgery outcomes. Vicarious Surgical leads in developing robotic technology to enhance surgical efficiency and patient care.